The Compliance of Varenicline With Short-massage
NCT01656083 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 220
Last updated 2012-08-02
Summary
Research indicated that the relapse rate of smokers who attempted to give up smoking without drug and other assistance is up to 90-95% while the successful cessation rate may be improved a lot with assistance to quit smoking. There are two kinds of measures to help smokers quit smoking: one is psychological and behavioral intervention, including the advice to quit smoking provided by doctors during daily health service and smoking cessation hotline; another is provision of drug therapy. 2008 smoking cessation Guidance plays emphasis on the effectiveness of smoking cessation of Varenicline and also on role of doctor's behavioral intervention in smoking cessation as Class A of evidence-based rating; among which, doctor's consultation (three minutes) at minimum intensity is effective; high-intensity consultation (more than ten minutes) is more effective than that of low-intensity consultation; and return visit for more than four times will distinctively improve the smoking abstinence rate. It is unrealistic to apply high-intensity and high-frequency smoking cessation intervention on all smokers due to the busy clinical work of domestic doctors. Systematic and standardized short message intervention system may be helpful to improve abstinence rate. Meanwhile, it can reduce human labor and physical resources, and improve the frequency of follow-up visit to smokers. It is observed during the process of offering smoking cessation services to smokers that, it would be one of the very effective measures to provide timely and useful information to smokers at several critical phases of smoking cessation course (such as three weeks before smoking cessation, prevention of relapse, etc.). Doctors, however, are usually passive during this period and unable to provide assistance to smokers with initiative. As people are more and more aware of the harmfulness of smoking and more and more smokers are increasingly willing to give up smoking, it is necessary to create an instant active information distribution system, which provides immediate active smoking cessation short message support through universally used mobile phone short message service to achieve the purpose of helping them quit smoking.
Conditions
- Smoking
Sponsors & Collaborators
-
yu hong xia
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2011-07-31
- Completion
- 2012-12-31
Countries
- Germany
More Related Trials
-
A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking
NCT00635401 ·Status: COMPLETED ·Phase: PHASE2
-
Varenicline and Combined NRT for Smoking Cessation
NCT02271919 ·Status: COMPLETED ·Phase: PHASE4
-
An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking
NCT00371813 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Varenicline: Testing Individual Differences
NCT01228175 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
NCT00282984 ·Status: COMPLETED ·Phase: PHASE3
-
Smoking Cessation Study In Healthy Adolescent Smokers
NCT01312909 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline and Nicotine Interactions in Humans (VA)
NCT00606892 ·Status: COMPLETED ·Phase: NA
-
Varenicline Light Smoking Pilot
NCT04089982 ·Status: COMPLETED ·Phase: PHASE4
-
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
NCT00143286 ·Status: COMPLETED ·Phase: PHASE3
-
Combining Varenicline and Guanfacine for Smoking Cessation
NCT04198116 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
NCT00717093 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline For Smokers In Recovery From Alcohol Dependence
NCT01092702 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation
NCT07099638 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment
NCT01309685 ·Status: WITHDRAWN ·Phase: PHASE1
-
Varenicline in Drug Treatment
NCT01286584 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline for Smoking Reduction in Veterans Not Ready To Quit
NCT06966362 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Varenicline for Light Smokers
NCT01639560 ·Status: COMPLETED ·Phase: PHASE4
-
Combining Varenicline and Naltrexone for Smoking Cessation
NCT02698215 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Varenicline Treatment for Smoking Cessation
NCT00828113 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
NCT00691483 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease
NCT01694732 ·Status: COMPLETED ·Phase: PHASE3
-
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00143299 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt
NCT00571805 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Extended Varenicline Treatment for Smoking Among Cancer Patients
NCT01756885 ·Status: COMPLETED ·Phase: PHASE3
-
Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation
NCT01444131 ·Status: COMPLETED ·Phase: PHASE2